Mannkind reported $-20454000 in Operating Profit for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Adma Biologics ADMA:US $ 16.96M 38.45M
Biocryst Pharmaceuticals BCRX:US $ -34.72M 15.24M
Chemocentryx CCXI:US $ -31.57M 6.66M
Dynavax Technologies DVAX:US $ 128.23M 97.46M
Eli Lilly And LLY:US $ 1210.1M 1194.2M
Halozyme Therapeutics HALO:US $ 34.06M 41.61M
Immunogen IMGN:US $ -61.05M 38.2M
Insmed INSM:US $ -88316000 1.52M
Karyopharm Therapeutics KPTI:US $ -42908000 8.32M
Macrogenics MGNX:US $ -41808000 24.83M
Mannkind MNKD:US $ -20.45M 0.8M
Merk MRK:US $ 4927M 642M
Minerva Neurosciences NERV:US $ -6.96M 1.02M
Novavax NVAX:US $ -482.96M 692.25M
Novo Nordisk A Fs NVO:US $ 18391M 756M
Peregrine Pharmaceuticals PPHM:US $ 1.07M 2.2M
Pfizer PFE:US $ 12102M 2229M
Xencor XNCR:US $ -28M 54.47M